Cargando…
Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects
IMPORTANCE: Neuromyelitis optica (NMO - including NMO spectrum disorders [NMOSD]) is a devastating disease. Eighty-three percent of patients with transverse myelitic (TM) attacks and 67% of patients with optic neuritis (ON) attacks have no or a partial recovery. OBSERVATIONS: Up until recently, ther...
Autor principal: | Brod, Staley A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539063/ https://www.ncbi.nlm.nih.gov/pubmed/33059216 http://dx.doi.org/10.1016/j.msard.2020.102538 |
Ejemplares similares
-
Therapy of NMO spectrum disorders
por: Biswas, Atanu, et al.
Publicado: (2015) -
Finding NMO
por: Daneman, Richard
Publicado: (2016) -
Neurodegeneration in MS and NMO: The Eye and the Blood
por: Petzold, Axel, et al.
Publicado: (2011) -
Neuromyelitis optica (NMO) and autoimmune thyroiditis
por: Sudulagunta, Sreenivasa Rao, et al.
Publicado: (2015) -
Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD
por: Zeka, Bleranda, et al.
Publicado: (2016)